GILD

#78
Gilead Sciences Inc
139.80 USD
+0.55%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
139.68
140.78
Jahresspanne
95.29
157.27
Tagesänderung
+0.55%
Monatliche Änderung
-3.07%
6 month change
+18.39%
Jahresänderung
+31.39%
Vorheriger Schlusskurs
139.03
Eröffnung
140.06
Bid
Ask
Tief
139.68
High
140.78
Volumen
570
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden
Vierteljährlich Jährlich
  • Market Capitalization 173.55 B
  • Employee 17 K
  • Founded 1987
  • CEO Daniel O'Day
  • Website www.gilead.com
  • Headquarter Delaware, United States
  • FIGI BBG000CKGBP2
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
18.1
Preis-Umsatz-Verhältnis
5.23
Dividende je Aktie
3.16
Dividendenrendite in %
2.57

Gilead Sciences Inc

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s. However, it came under heavy scrutiny over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world.

Nachrichten